Global Heart · 2021 · 14 citations · 14 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyPharmacovigilancePreventive CardiologyArrhythmia PharmacotherapyCardiovascular MonitoringElectrocardiographyPatient MonitoringPharmacotherapy MonitoringVital Signs Recording12-Lead ElectrocardiographyControl Group DesignHydroxychloroquine TherapyHydroxychloroquine TreatmentMatched Control GroupQt Interval AnalysisQt Interval Assessment
Background: QTc prolongation is an adverse effect of COVID-19 therapies. The use of a handheld device in this scenario has not been addressed. Objectives: To evaluate the feasibility of QTc monitoring with a smart device in COVID-19 patients receiving QTc-interfering therapies. Methods: Prospective study of consecutive COVID-19 patients treated with hydroxychloroquine ± azithromycin ± lopinavir-ritonavir. ECG monitoring was performed with 12-lead ECG or with KardiaMobile-6L. Both registries were also sequentially obtained in a cohort of healthy patients. We evaluated differences in QTc in COVID-19 patients between three different monitoring strategies: 12-lead ECG at baseline and follow-up (A), 12-lead ECG at baseline and follow-up with the smart device (B), and fully monitored with handheld 6-lead ECG (group C). Time needed to obtain an ECG registry was also documented. Results: One hundred and eighty-two COVID-19 patients were included (A: 119(65.4%); B: 50(27.5%); C: 13(7.1%). QTc peak during hospitalization did significantly increase in all groups. No differences were observed between the three monitoring strategies in QTc prolongation (p = 0.864). In the control group, all but one ECG registry with the smart device allowed QTc measurement and mean QTc did not differ between both techniques (p = 0.612), displaying a moderate reliability (ICC 0.56 [0.19-0.76]). Time of ECG registry was significantly longer for the 12-lead ECG than for handheld device in both cohorts (p < 0.001). Conclusion: QTc monitoring with KardiaMobile-6L in COVID-19 patients was feasible. Time of ECG registration was significantly lower with the smart device, which may offer an important advantage for prevention of virus dissemination among healthcare providers.
14
Azithromycin and the Risk of Cardiovascular Death
Wayne A. Ray, Katherine T. Murray, Kathi Hall et al. · New England Journal of Medicine · 2012 · 968 citations · Full text
Medicine, Cardiology, Pharmacology +15
Hao‐Yuan Cheng, Shu-Wan Jian, Ding‐Ping Liu et al. · JAMA Internal Medicine · 2020 · 959 citations · Full text
Veterinary Medicine, Infectious Disease Control, Infectious Diseases +16
John R. Giudicessi, Peter A. Noseworthy, Paul A. Friedman et al. · Mayo Clinic Proceedings · 2020 · 404 citations · Full text